Pharvaris moves closer to bringing second oral on-demand HAE therapy to US
Pharvaris is advancing its efforts to introduce a second oral on-demand therapy for Hereditary Angioedema (HAE) in the US. This move signals potential new treatment options for patients. The article focuses on the company's progress and the implications for the HAE market.
Chiesi to Acquire KalVista Pharmaceuticals in $1.9 Billion Deal
Chiesi Farmaceutici S.p.A. is set to acquire KalVista Pharmaceuticals, Inc. in a deal valued at $1.9 billion. Ropes & Gray advised Chiesi Farmaceutici, while Kirkland & Ellis and Fenwick & West advised KalVista Pharmaceuticals on the transaction. The full details of the acquisition are accessible to standard 1-year members of Global Legal Chronicle.
Enterprise value to revenue forward of KalVista Pharmaceuticals, Inc. – SWB:4XC1
This article provides key financial data focusing on the enterprise value to revenue forward for KalVista Pharmaceuticals, Inc. (SWB:4XC1) on the Stuttgart Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content is primarily a data placeholder within a financial information platform.
Price to book forward of KalVista Pharmaceuticals, Inc. – SWB:4XC1
This article provides financial information for KalVista Pharmaceuticals, Inc. (SWB:4XC1), focusing on its forward price-to-book value. It indicates that the market was closed with no trades at the time of the report. The content specifies the period, value, and change for this financial metric, noting that the data is made by humans.
KALV Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for KALV (KalVista Pharmaceuticals Inc.). It details upcoming earnings dates, revenue and EPS estimates from analysts, and historical stock price reactions to past earnings reports. The report also touches on the sentiment from the Q3 2025 earnings call, highlighting both positives like early market adoption of EKTERLY and concerns regarding financial guidance.
[15-12G] KalVista Pharmaceuticals, Inc. SEC Filing
KalVista Pharmaceuticals, Inc. has filed a Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) and suspension of duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. This filing indicates that the company now has only one holder of record. The move follows recent news including Chiesi Group's acquisition of KalVista Pharmaceuticals.
Kalvista Pharmaceuticals Inc (KALV) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Kalvista Pharmaceuticals Inc (KALV), outlining both its major shareholders and institutional holdings. Key data includes a breakdown of top individual shareholders and their respective proportions, as well as institutional ownership trends over several quarters, showing changes in shares held and proportion. The report also categorizes shareholder types and lists related ETFs with Kalvista Pharmaceuticals holdings.
Kalvista Pharmaceuticals Inc (KALV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
The article discusses Kalvista Pharmaceuticals Inc (KALV) and notes that relevant data regarding its revenue breakdown by business segments and regions, as well as profit contribution, has not been disclosed by the company. It provides general stock information for KALV, including its current price and market capitalization, but emphasizes the lack of detailed financial segment data.
Kalvista Pharmaceuticals Inc (KALV) Earnings Forecast: Future EPS & Revenue Growth Estimates
Kalvista Pharmaceuticals Inc (KALV) currently holds an earnings forecast score of 6.57, placing it 328th out of 390 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00 for KALV, with expectations for the next quarter's revenue at $13.08 million and EPS at -$0.23. Based on ratings from three analysts, the stock is generally considered a "Hold."
[EFFECT] KalVista Pharmaceuticals, Inc. SEC Filing
This article reports on an SEC filing (Form EFFECT) by KalVista Pharmaceuticals, Inc. (KALV), indicating the effectiveness of a previous submission with the SEC as of June 16, 2026. The filing is deemed neutral in both impact and sentiment. The article also provides a company overview, recent news, and other SEC filings for KalVista Pharmaceuticals.
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9 Billion
Chiesi Group has finalized its acquisition of KalVista Pharmaceuticals for approximately $1.9 billion, marking its largest deal to date. This acquisition brings KalVista's oral, on-demand treatment for hereditary angioedema (HAE) into Chiesi's portfolio, enhancing its rare disease offerings. The deal involved Chiesi acquiring all outstanding shares for $27.00 per share in cash, a significant premium to KalVista's 30-day volume-weighted average share price prior to the announcement.
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 2500 Index
KalVista Pharmaceuticals, Inc. (NasdaqGM:KALV) has been removed from the Russell 2500 Index, among other Russell indices, effective June 14, 2026. This announcement, published by S&P Capital IQ, indicates multiple removals from various Russell Growth and Dynamic indices. KalVista Pharmaceuticals is known for developing EKTERLY, an oral treatment for hereditary angioedema (HAE).
KalVista Pharmaceuticals, Inc.(NasdaqGM: KALV) dropped from Russell 2500 Growth Index
KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) has been removed from the Russell 2500 Growth Index as of June 14, 2026. This exclusion is one of several from various Russell indices announced on the same date, indicating a revised position for the company in these market benchmarks. KalVista specializes in developing treatments for hereditary angioedema (HAE), with its primary drug EKTERLY being an oral on-demand treatment.
Chiesi Group Completes $1.64 Billion Acquisition Of KalVista Pharmaceuticals
Chiesi Group has completed its $1.64 billion acquisition of KalVista Pharmaceuticals, integrating the rare disease drug developer into its global organization. This strategic move strengthens Chiesi's Rare Diseases business unit and grants it ownership of EKTERLY (sebetralstat), an approved oral treatment for hereditary angioedema. The acquisition, finalized in June 2026, saw KalVista shareholders receiving $27.00 per share.
KalVista (NASDAQ: KALV) director options cashed out, canceled in Chiesi deal
KalVista Pharmaceuticals director Nancy Stuart's stock options were cashed out or canceled as part of the company's acquisition by Chiesi Farmaceutici. Under the merger agreement, options with an exercise price below $27.00 per share were vested, canceled, and converted into cash, while options at or above $27.00 were canceled without payment. This transaction resulted in no remaining derivative positions for Stuart after the merger became effective on June 11, 2026.
KalVista (NASDAQ: KALV) deregisters S-3 securities after merger
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has filed a Post-Effective Amendment No. 1 to its Form S-3 to deregister remaining unsold securities following its merger with Skyline Merger Sub, Inc. on June 11, 2026. This merger made KalVista a wholly owned subsidiary of Chiesi Farmaceutici S.p.A., rendering the previous S-3 registration statement obsolete. The deregistration is an administrative action to formalize the termination of offerings under the original registration statement.
KalVista (KALV) director closes out 91,000 options in $27-per-share Chiesi merger
KalVista Pharmaceuticals director Brian JG Pereira disposed of 91,000 fully vested stock options as part of the company's merger with Chiesi Farmaceutici. The options were converted into cash rights based on the difference between the $27.00 per share merger price and each option's exercise price. This transaction resulted in no remaining derivative holdings for Pereira, reflecting the typical settlement of equity awards in all-cash mergers where KalVista became a wholly-owned subsidiary of Chiesi.
KalVista (NASDAQ: KALV) taken private in $27 cash sale to Chiesi Group
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, taking the company private in an all-cash deal at $27.00 per share. The transaction involved a tender offer for approximately 77.8% of outstanding shares, followed by a short-form merger, making KalVista a wholly owned subsidiary of Chiesi. KalVista's stock has ceased trading on Nasdaq, and the company plans to deregister its shares and suspend SEC reporting.
KalVista (KALV) director’s stock options cancelled or cash-settled in Chiesi takeover
KalVista Pharmaceuticals director William Fairey's stock options were cancelled or cash-settled as a mechanical outcome of the company's merger with Chiesi Farmaceutici. This Form 4 filing details the disposition of three stock option awards, totaling 57,000 shares, on June 11, 2026. In-the-money options were converted to cash rights based on the $27.00 per share merger consideration, while out-of-the-money options were cancelled without payment.
Kalvista Pharmaceuticals, Inc. Announces Management Changes
KalVista Pharmaceuticals, Inc. announced significant management changes following the completion of its merger with Chiesi Farmaceutici S.p.A. The entire board of directors, including Brian J. G. Pereira, Benjamin L. Palleiko, and others, resigned. John Hess, previously the sole director of the acquiring entity, assumed the role of sole director and an officer of KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Sets $1,606.28 Cash Conversion for 3.25% Converts via Supplemental Indenture
KalVista Pharmaceuticals has entered into a supplemental indenture for its 3.250% Convertible Senior Notes due 2031. Following a merger, each $1,000 principal amount of notes is now convertible into $1,606.28 in cash. This amendment ensures a cash-only settlement and aligns noteholder rights with the merger's cash consideration of $27.00 per share.
KalVista Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing
KalVista Pharmaceuticals has notified Nasdaq of the completion of its merger, requesting the suspension of trading and the removal of its shares from The Nasdaq Global Market. Trading ceased on June 11, 2026, and the company plans to file Form 15 to terminate registration and suspend reporting obligations. This information is based on an SEC filing from June 11, 2026.
KalVista (NASDAQ: KALV) CMO’s stock, RSUs and options cancelled in $27-per-share Chiesi merger cleanup
KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, had his equity awards cancelled following the company's merger into a Chiesi Farmaceutici S.p.A. subsidiary. His holdings, including 150,260 shares of common stock, various restricted stock units (RSUs), and stock options, were disposed of on June 11, 2026, as part of the merger agreement. In-the-money options and RSUs were converted to cash at $27.00 per share, while out-of-the-money options were cancelled without payment, leaving Audhya with no remaining holdings.
KalVista Pharmaceuticals (KALV) CFO exits equity as Chiesi cash deal closes
KalVista Pharmaceuticals' CFO, Brian Piekos, disposed of all his equity holdings, including common shares, restricted stock units, and stock options, as part of the company's acquisition by Chiesi Farmaceutici. These transactions were not open-market sales but were cashing out of equity awards according to the merger agreement, which valued KalVista common shares at $27.00 each. Following the merger, Piekos holds no remaining reported equity in the now wholly-owned subsidiary.
KalVista (NASDAQ: KALV) COO’s RSUs and options cashed out in Chiesi merger
KalVista Pharmaceuticals' COO, Arif Bilal, disposed of 49,000 restricted stock units and 100,000 stock options as part of the company's acquisition by Chiesi Farmaceutici. These equity awards were cashed out at $27.00 per share, with both RSUs and in-the-money options fully vesting and converting into cash payments according to the merger agreement. Underwater options were cancelled without payment in this standard equity clean-up following a change-of-control transaction, as reported in a recent SEC Form 4 filing.
Chiesi deal cancels options for KalVista (KALV) director Edward Unkart
KalVista Pharmaceuticals director Edward W. Unkart surrendered 109,000 stock options as part of the company's acquisition by Chiesi Farmaceutici. The options were cancelled and converted into a cash payment based on the $27.00 per share merger consideration and their respective exercise prices. This Form 4 filing reports these dispositions to the issuer, indicating a full cash-out of the director's options tied to the merger closing rather than a standard market transaction.
KalVista (NASDAQ: KALV) CDO disposes equity in $27-per-share Chiesi deal
KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, has disposed of all his equity holdings in the company as part of its merger with Chiesi Farmaceutici. This transaction involved the conversion of common shares into cash at $27.00 per share, and the cancellation or cash conversion of restricted stock units and stock options based on their exercise prices relative to the merger consideration. The disposition reflects a corporate transaction rather than an open-market trade, leaving Yea with no reported equity in KalVista post-merger.
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
Chiesi Group has announced the completion of its acquisition of KalVista Pharmaceuticals. Through this acquisition, KalVista will become part of Chiesi's Rare Diseases business unit, expanding patient access and accelerating impact in rare diseases, particularly with EKTERLY® (sebetralstat), an oral treatment for hereditary angioedema (HAE) attacks. The acquisition involved a tender offer for $27.00 per share, making KalVista a wholly-owned subsidiary of Chiesi.
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B
Chiesi Group, a biopharmaceutical company, has acquired KalVista Pharmaceuticals Inc. for approximately $1.9 billion. This acquisition integrates KalVista into Chiesi Group's Rare Diseases business unit, expanding its focus on therapies for rare conditions. A key asset gained is EKTERLY (sebetralstat), an approved oral treatment for hereditary angioedema (HAE) attacks, which will now be further developed and commercialized globally by Chiesi.
Chiesi Group Acquires KalVista Pharmaceuticals (KALV)
Chiesi Group has finalized its acquisition of KalVista Pharmaceuticals for $27.00 per share, purchasing approximately 77.8% of the company's outstanding stock. This strategic acquisition bolsters Chiesi's Rare Diseases division and grants them ownership of EKTERLY, an FDA-approved oral medication for hereditary angioedema. KalVista Pharmaceuticals, previously valued at $1.44 billion, will no longer be listed on Nasdaq, and despite the move, KalVista showed significant financial weaknesses with a GF Score™ of 19/100, and insider selling activity totaling $5.8 million.
Chiesi completes acquisition of KalVista for $27 per share
Chiesi Group has finalized its acquisition of KalVista Pharmaceuticals, Inc., for $27.00 per share in cash, resulting in KalVista becoming a wholly owned subsidiary. The acquisition grants Chiesi ownership of EKTERLY (sebetralstat), an FDA-approved treatment for hereditary angioedema attacks. KalVista, valued at $1.44 billion in the transaction, saw its stock cease trading on Nasdaq Global Market, with analysts downgrading ratings to align with the acquisition price.
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, making KalVista a wholly owned subsidiary. This acquisition broadens Chiesi's Rare Diseases business unit and includes ownership of EKTERLY (sebetralstat), an approved oral treatment for hereditary angioedema (HAE) attacks. The transaction was finalized following a tender offer for KalVista's common stock at $27.00 per share.
KalVista (KALV) acquisition closes; 43.15M shares tendered at $27.00
The acquisition of KalVista Pharmaceuticals (KALV) has been completed, with 43.15 million shares, representing approximately 77.8% of outstanding shares, tendered at $27.00 per share. The tender offer met the minimum condition, and the purchaser merged with KalVista under Section 251(h) of the DGCL. As a result, KalVista's common stock will be delisted from the Nasdaq Global Market.
Capital World Investors Sells 369,004 Shares of KalVista Pharmaceuticals, Inc. $KALV
Capital World Investors reduced its stake in KalVista Pharmaceuticals by 11.6% in the fourth quarter, selling over 369,000 shares. This comes amidst continued insider selling and recent analyst re-ratings of the stock from "buy" to "hold" by several firms. Despite a narrower-than-expected loss in its last quarterly earnings report, the company's stock has faced downward pressure from these institutional and insider transactions.
Kalvista Pharmaceuticals stock hits 52-week high at $27.00 By Investing.com
Kalvista Pharmaceuticals (KALV) stock has reached a 52-week high of $27.00, driven by investor confidence and an announced merger agreement with Chiesi Group. Chiesi will acquire KalVista for $27.00 per share in cash, valuing the company at $1.9 billion, a 36% premium over its 30-day volume-weighted average share price. Analysts have revised earnings estimates upwards, though some firms have downgraded their ratings to Neutral or Hold, aligning price targets with the acquisition price.
Glazer Capital (KALV) reports 2.58M shares, 4.85% stake
Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G indicating beneficial ownership of 2,581,700 shares of KalVista Pharmaceuticals, Inc. (KALV) Common Stock, representing 4.85% of the class. The filing specifies shared voting and dispositive power over these shares and states that the reporting persons have ceased to be beneficial owners of more than five percent of the class. This is a passive reporting position, as indicated by the Schedule 13G filing.
Kalvista Pharmaceuticals stock hits 52-week high at $27.00
Kalvista Pharmaceuticals (KALV) stock reached a 52-week high of $27.00, boasting a 67% year-to-date return and a 100.52% one-year change. This surge is attributed to investor confidence and four analysts revising earnings upwards. The company also announced a merger agreement with Chiesi Group, where Chiesi will acquire KalVista for $27.00 per share, valuing it at approximately $1.9 billion.
KalVista Pharmaceuticals (KALV) Stock Forum and Discussion
This article provides a forum for discussion regarding KalVista Pharmaceuticals (KALV) stock. It likely includes investor opinions, news, and analysis related to the company's performance and future outlook. The content serves as a platform for shareholders and interested parties to exchange information and insights.
KalVista Pharmaceuticals, Inc. Revenue Breakdown – XETR:4XC1
This article provides a revenue breakdown for KalVista Pharmaceuticals, Inc. (XETR:4XC1). The company generated 41.79 million EUR last year, with its Plasma Kallikrein Inhibitor segment being the top performer at 62.68 million EUR. The United States was the largest contributor to revenue at 62.68 million EUR.
Cost of goods sold of KalVista Pharmaceuticals, Inc. – XETR:4XC1
This article displays the "Cost of goods sold" for KalVista Pharmaceuticals, Inc. (XETR:4XC1). It presents a data point indicating the value and percentage change for this financial metric over a specified period. The content is presented in a table format, allowing for quick reference to the financial data.
KalVista Pharmaceuticals, Inc. Cash Flow – XETR:4XC1
KalVista Pharmaceuticals, Inc. (XETR:4XC1) reported a free cash flow of -12.62 million EUR for Q1 2026 and -70.95 million EUR for 2025, with an operating cash flow of -69.49 million EUR for 2025. The financial overview presents key cash flow activities, including operating, investing, and financing, with data available up to 2025 for annual and quarterly metrics.
KalVista Pharmaceuticals, Inc. Balance Sheet – XETR:4XC1
KalVista Pharmaceuticals, Inc. (XETR:4XC1) reported its Q1 2026 financial position, showing total assets at EUR 284.69 million, a 0.30% decrease from Q4 2025. Concurrently, total liabilities for Q1 2026 rose by 4.81% to EUR 301.69 million. The article provides an overview of the company's financial statements, including balance sheet data.
Liquidity Mapping Around (KALV) Price Events
This article analyzes Kalvista Pharmaceuticals Inc. (NASDAQ: KALV) using AI models to provide liquidity mapping and trading strategies. It identifies a neutral near and mid-term outlook but a long-term positive bias, noting no clear price positioning signals above the current price. The piece outlines specific position, momentum, and risk-hedging trading strategies for various risk profiles.
Injectable treatments for HAE attacks may add stress for children
Injectable on-demand treatments for children with hereditary angioedema (HAE) often lead to anxiety, pain, treatment delays, and high emergency healthcare service use, according to data from Kalvista Pharmaceuticals. A claims database analysis and caregiver surveys highlighted the burden of injectable therapies, including significant off-label use and difficulties in administration. These findings underscore the critical need for simpler, less invasive treatment options, particularly oral alternatives, to enhance the treatment experience for pediatric HAE patients and their families.
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests an improvement in the company's underlying business and could lead to a favorable impact on its stock price. The Zacks rating system highlights stocks with strong earnings estimate revisions, making KALV a solid candidate for potential market-beating returns.
Assessing KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Shareholder Returns
KalVista Pharmaceuticals has seen significant share price appreciation over the past year, with a 127.71% total shareholder return, yet remains undervalued according to Simply Wall St's narrative, setting a fair value at $31.00 compared to its current $26.87. Despite international expansion plans and a projected steep revenue increase, analysts point out meaningful valuation risk due to a high P/S ratio of 12.5x against an estimated fair ratio of 5.9x. The report advises investors to review the company's key rewards and warning signs to make an informed decision.
KalVista (KALV) discloses two shareholder suits, reiterates $27.00/share deal
KalVista Pharmaceuticals (KALV) has amended its Schedule 14D-9, disclosing two shareholder lawsuits in New York state court contesting the company's planned acquisition by Chiesi Farmaceutici S.p.A. The filing reaffirms the $27.00 per share cash offer, which was the culmination of previous proposals from Chiesi. KalVista maintains that the claims are without merit and highlights that regulatory clearances for the acquisition, including HSR expiration, have been obtained.
Chiesi (KALV) offers $27.00/share; HSR, German and Italian clearances noted
Chiesi Farmaceutici, through its subsidiary Skyline Merger Sub, has offered to acquire all outstanding shares of KalVista Pharmaceuticals (KALV) for $27.00 per share in cash. The tender offer has secured key regulatory clearances, including the expiration of the HSR Act waiting period, German GWB approval, and Italian foreign direct investment authority non-objection. The filing also notes that twelve demand letters and two individual complaints have been received, alleging disclosure deficiencies and seeking injunctions or damages.
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
KalVista Pharmaceuticals' (KALV) Chief Development Officer, Christopher Yea, sold 33,800 shares for approximately $905,000 on May 27, 2026, after exercising vested options. This transaction is notable because it occurred shortly before an anticipated buyout offer from Chiesi Group for $27 per share, slightly above Yea's selling price of $26.78. The company, focused on rare diseases, launched its lead drug Ekterly in July 2025, which generated $49 million in sales despite the company reporting a loss, highlighting the strategic value of the acquisition for Chiesi's rare disease segment.
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period
KalVista Holdings announced that its revenue from the drug EKTERLY totaled $49.1 million during an eight-month transition period that concluded on February 29, 2024. The company stated this revenue represents the performance of EKTERLY during its first eight months on the market.
